Betablocker (Nebivolol titrated to a target dose of 10mg/day) vs placebo

Study population:

Patients >70 years old with mild-severe heart failure (NYHA I-IV) irrespective of LVEF.

Comments:

Median age of patients was 75 years

64% of patients had a LVEF of </=0.35. >95% of enrolled patients were NYHA class II or III
>87% were already taking an ACE inhibitor or Angiotensin receptor blocker

Outcome	Duration	NNT	Annualised NNT
Prevent one death (all cause)	21 months (mean duration of followup)	44	78

References

Flather M, Shibata M, Coats A, Van Velhuisen D, Parkhomenko A. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2005; 26: 215-225.